This platform improves pharmacokinetic properties through fatty acid modification (LipoVantageTM platform) and antibody-peptide conjugation (APCVantageTM platform) to enable extended dosing intervals from weekly to monthly or potentially longer.

The platform enhances patient convenience and compliance by extending peptide half-life through systematic optimization including selection of conjugation sites, refinement of peptide sequences to optimize enzymatic stability, and structural tuning of fatty acids. We utilize various modification strategies offering customized approaches tailored to specific therapeutic demands and integrated pharmacokinetic evaluation systems across multiple species for early identification of optimal modifications.